No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T11:15:53.874Z. Latest historical point 2023-08-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Bluejay Diagnostics, Inc. (BJDX) stock was $0.76 as of Oct 5, 2026, 4:00 PM EDT, down 9.01% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -87.5% · 3-year avg -95.1%/yr
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions.
Medical - Devices · Acton, MA
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-3520.00
Revenue Est.
N/A
Last Quarter Results
EPS
$-2848.00
vs Estimate
$-1360.00
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BJDX | $787,624 | $0.76 | -9.01% | -87.52% | N/A | N/A | N/A |
| 2CDT | $707,297 | $0.92 | -7.30% | N/A | N/A | N/A | vs BJDX |
| 3BBLG | $878,396 | $0.49 | +2.06% | -80.44% | N/A | N/A | vs BJDX |
| 4DCOY | $888,387 | $1.67 | -5.65% | -96.49% | -86.39% | -79.17% | vs BJDX |
| 5ASBP | $1.02M | $8.88 | +1.14% | -98.04% | N/A | N/A | vs BJDX |
| 6CMND | $1.11M | $6.00 | +4.90% | -99.81% | N/A | N/A | vs BJDX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$0.76
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-3520.00 | $-3520.00 | $-3520.00 | 1 |
| Quarter ending Dec 2026 | $-3520.00 | $-3520.00 | $-3520.00 | 1 |
| Quarter ending Mar 2027 | $-2560.00 | $-2560.00 | $-2560.00 | 1 |
| Quarter ending Jun 2027 | $-2560.00 | $-2560.00 | $-2560.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-464.00 | $-464.00 | $-464.00 | 1 |
| FY 2027 | $-32.00 | $-32.00 | $-32.00 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $809000.00 | $809000.00 | $809000.00 | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $7.86M | $7.86M | $7.86M | 1 |
| FY 2027 | $18.48M | $18.48M | $18.48M | 1 |
